PMID- 22015232
OWN - NLM
STAT- MEDLINE
DCOM- 20120420
LR  - 20181201
IS  - 1879-1484 (Electronic)
IS  - 0021-9150 (Linking)
VI  - 220
IP  - 1
DP  - 2012 Jan
TI  - Effect of cilostazol on the progression of carotid intima-media thickness: a 
      meta-analysis of randomized controlled trials.
PG  - 177-83
LID - 10.1016/j.atherosclerosis.2011.09.048 [doi]
AB  - BACKGROUND: It has been well established that cilostazol has anti-proliferative 
      effect against in-stent restenosis. However, it remains unclear whether 
      cilostazol can prevent the progression of carotid atherosclerosis. METHODS AND 
      RESULTS: We performed a meta-analysis of all relevant randomized controlled 
      trials (RCTs) to evaluate the effect of cilostazol on the progression of carotid 
      intima-media thickness (IMT). Five RCTs with 698 patients [597 subjects with type 
      2 diabetes mellitus (T2DM)] were included in this study. Cilostazol was 
      associated with a significant reduction in the progression of carotid IMT (WMD, 
      -0.08mm, 95% CI -0.13, -0.04; P=0.00003). Subgroup analysis shows that cilostazol 
      monotherapy or addition to dual antiplatelet therapy (aspirin and clopidogrel) 
      was superior to placebo (WMD, -0.04mm, 95% CI -0.05, -0.03; P<0.00001), no 
      antiplatelet medication (WMD, -0.12mm, 95% CI -0.21, -0.03; P=0.008), aspirin 
      monotherapy (WMD, -0.06mm, 95% CI -0.12, 0.00; P=0.04) or dual antiplatelet 
      therapy (WMD, -0.16mm, 95% CI -0.30, -0.02; P=0.03) in preventing the progression 
      of carotid IMT. Cilostazol resulted in a significant decrease in total 
      cholesterol (WMD -8.47mg/dl, 95% CI -14.18, -2.75; P=0.004) and LDL-C (WMD 
      -8.25mg/dl, 95% CI -14.15, -2.36; P=0.006) and favorable trends in reducing 
      triglyceride (WMD -15.83mg/dl, 95% CI -32.14, 0.48; P=0.06). CONCLUSION: It 
      suggests that cilostazol may have beneficial effects in preventing the 
      progression of carotid atherosclerosis and improving pro-atherogenic lipid 
      profile, especially in patients with T2DM. Whether the anti-atherosclerotic 
      effect of cilostazol is independent of improving pro-atherogenic dyslipidemia is 
      worth further investigation.
CI  - Copyright (c) 2011 Elsevier Ireland Ltd. All rights reserved.
FAU - Geng, Deng-Feng
AU  - Geng DF
AD  - Department of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 
      No. 107 West Yanjiang Road, Guangzhou 510120, China.
FAU - Deng, Jing
AU  - Deng J
FAU - Jin, Dong-Mei
AU  - Jin DM
FAU - Wu, Wei
AU  - Wu W
FAU - Wang, Jing-Feng
AU  - Wang JF
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20111004
PL  - Ireland
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
RN  - 0 (Phosphodiesterase 3 Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tetrazoles)
RN  - N7Z035406B (Cilostazol)
SB  - IM
MH  - Aged
MH  - Carotid Artery Diseases/diagnosis/*drug therapy/pathology
MH  - *Carotid Intima-Media Thickness
MH  - Cilostazol
MH  - Disease Progression
MH  - Drug Therapy, Combination
MH  - Evidence-Based Medicine
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Phosphodiesterase 3 Inhibitors/adverse effects/*therapeutic use
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - *Randomized Controlled Trials as Topic
MH  - Tetrazoles/adverse effects/*therapeutic use
MH  - Treatment Outcome
EDAT- 2011/10/22 06:00
MHDA- 2012/04/21 06:00
CRDT- 2011/10/22 06:00
PHST- 2011/06/21 00:00 [received]
PHST- 2011/09/15 00:00 [revised]
PHST- 2011/09/27 00:00 [accepted]
PHST- 2011/10/22 06:00 [entrez]
PHST- 2011/10/22 06:00 [pubmed]
PHST- 2012/04/21 06:00 [medline]
AID - S0021-9150(11)00954-3 [pii]
AID - 10.1016/j.atherosclerosis.2011.09.048 [doi]
PST - ppublish
SO  - Atherosclerosis. 2012 Jan;220(1):177-83. doi: 
      10.1016/j.atherosclerosis.2011.09.048. Epub 2011 Oct 4.